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EFFECTS ON LIPID METABOLISM OF METFORMIN AND TROGLITAZONE IN
PATIENTS WITH TYPE 2 DIABETES MELLITUS
INGI LEE, DAVID G. MAGGS, DAVID KATZ, GERALYN R. SPOLLETT, STEPHANIE L.
PAGE, FRANCES S. RIFE, and SILVIO E. INZUCCHI, Section of Endocrinology, Department
of Medicine, Yale University School of Medicine, New Haven, CT
Biguanides and the thiazolidinediones (TZDs) have distinct anti-hyperglycemic
mechanisms of action. Both classes also influence lipid metabolism but have not been adequately
compared. We measured the effects on lipid parameters of metformin (M), a biguanide, and
troglitazone (T), a TZD, alone and in combination (MT), in 27 type 2 diabetic subjects. Random
assignment was made to either M (1000 mg BID; n=15) orT (400 mg QD; n=12) for 3 mo.
Baseline characteristics were similar between groups: mean age 53.4 years, HbAlc 9.5%, and
BMI 33.7 kg/m2. After 3 mo. of M or T, subjects were placed on MT (n=23) for another 3 mo.
There was an insignificant rise in HDL-C with M or T (+6%) and an additive effect with
MT (+12%, p<.01). M decreased LDL-C by 7.5% (p=.04), T insignificantly increased levels
(+8.1%), and MT had a neutral effect. Both M (-15.3%) and T (-16.4%) insignificantly reduced
fasting (f-) TG; MT decreased f-TG by 27.0% (p<.01). A similar pattern was seen on
postprandial (pp-) TG (M, -9.8% (p=NS); T, -9.7% (p=NS); MT, -15.1% (p=.006)). M did not
affect f-FFA, whereas there was a reduction with T (-30.0%, p=.03), partially offset by MT
(-17.3%, p<0.01). In contrast, both agents decreased pp-FFA, with T having a greater effect (M,
-32.7% (pc.Ol); T, -48.7% (p=.001)), and little evidence for additive effect (-53%, p<.0001).
The effects of MT on HDL-C, f-TG, and pp-TG seem to be additive, while their effects
on LDL-C appear offsetting. T elicits a clear suppression of both f-FFA and pp-FFA, whereas M
does not affect f-FFA and induces a less potent suppression of pp-FFA. In combination, M
attenuates T's f-FFA effects, and there is only minimal additive benefit on pp-FFA. Overall, both
agents have generally favorable, although differing, effects on lipid metabolism, with only some
synergy demonstrated in combination.
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INTRODUCTION
Prevalence and Pathophysiology of Type 2 Diabetes Mellitus
Diabetes mellitus (DM) is a serious and common health problem. In the US alone, 16
million individuals are affected by DM; approximately 90% of these patients have type 2 DM
(T2DM) (1). As the number of affected patients continues to increase, the National Health and
Nutrition Examination Survey states that diabetes will become the most common chronic disease
in this country (1). The national cost of treating diabetes as well as its complications (DM is the
leading cause of blindness and renal failure) accounts for 1/6 of all health care expenditures (1).
Intrinsic genetic factors contribute significantly to the pathogenesis of this disease. DM
is found more often within certain ethnic groups including Hispanics, African Americans, Pacific
Islanders, and Native American Indians. Twin studies have also shown that monozygotic twins
have a twofold or greater concordance as compared to dizygotic twins (2). Though researchers
have sought to isolate individual candidate genes or clusters of genes, none have been found,
suggesting that DM involves multiple defects in various genes. Acquired factors including
increasing age, visceral obesity, and physical inactivity have also been correlated with the
development and progression of this disease.
T2DM is defined by the presence of peripheral insulin resistance and non-autoimmune
impaired insulin secretion. It begins with a compromise in insulin action. Peripheral insulin
resistance occurs most notably in skeletal muscle and adipose tissue, resulting in decreased
glucose disposal. Unimpaired glucagon secretion coupled with hepatic insulin resistance results
in elevated basal hepatic glucose output. Adipocytes release free fatty acids (FFA), which along
with glucose, are transported to the liver for triglyceride (TG) synthesis. TG becomes an
alternative energy source for tissues such as muscle, thereby conserving glucose for the central
nervous system. Not only is plasma glucose and FFA elevation a result of insulin resistance, but
each also independently exacerbates insulin resistance (“glucotoxicity”, “lipotoxicity”). FFA
oxidation also further stimulates gluconeogenesis in the liver. Pancreatic (3 cell hyperplasia

occurs to increase insulin output. With worsening insulin resistance, however, the level of
hyperinsulinemia becomes relatively insufficient, resulting in mild hyperglycemia, initially
detected in the postprandial setting.

(3 cell dysfunction soon follows. The decreased insulin

response to glucose eventually results in elevated fasting blood sugar levels. The etiology of (3
cell dysfunction is unknown but suspected etiologies include genetically programmed failure,
glucotoxicity, and/or lipotoxicity.

Diabetic Complications

Microvascular complications
Patients with T2DM are at a higher risk of developing microvascular and macrovascular
complications compared to those unaffected by the disease. Up to 20% of patients with T2DM
are found to have retinopathy and 7-8% are found to have neuropathy at the time of clinical
diagnosis (3). The incidence of microvascular complications then rises as the duration of T2DM
increases. Approximately 9% of previously unaffected patients develop neuropathy,
nephropathy, and/or retinopathy within 9 years of diagnosis (4).
The Diabetes Control and Complications Trial (DCCT), a large prospective multicenter
study of type 1 diabetics, was the first to demonstrate the causal role of hyperglycemia in
microvascular complications and thus, establish the importance of strict glucose control in these
patients (5). As expected, the Kumamoto Study (6), the Veteran Affairs Cooperative Study (7),
and the United Kingdom Prospective Diabetes Study (UKPDS) (8) all went on to further
demonstrate that type 2 diabetics would similarly benefit from aggressive glucose control.

Macrovascular complications
Although microvascular complications increase morbidity, macrovascular complications
take the greater toll on T2DM patients. Atherosclerosis accounts for 80% of the mortality rate,
with cardiovascular disease (CVD) being the number one cause of death in these patients (9).
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Atherosclerosis-related morbidity, including coronary artery disease (CAD), stroke, and
peripheral vascular disease (PVD) is also 2.5 times higher in diabetic men and 3.5-4.5 times
higher in diabetic women than in their non-diabetic counterparts (10, 11, 12).
The main goal of current diabetes treatment is to strictly control glucose levels. Although
this has been shown to benefit microvascular complications, its role on macrovascular
complications has not been fully supported. A Finnish study showed that elevated levels of
glycosylated hemoglobin (HbAlc) may mediate CVD in elderly diabetics through the formation
of advanced glycation end products in vessel walls (13). A number of other theories have linked
the genesis of atherosclerosis to endothelial dysfunction, or frequently coexisting hypertension
and hyperlipidemia.
Interventional studies have yielded interesting yet inconclusive results. The Veterans
Affairs Cooperative Study (7) and the UKPDS (8) both found insignificant differences in
macrovascular complications between their intensively treated and conventionally treated groups.
When the UKPDS subgroups were further analyzed, however, researchers found that the group
intensively treated with metformin had a significant 39% reduction in the incidence of myocardial
infarction (MI) compared to patients treated conventionally with diet or intensively with
sulfonylureas or insulin. This finding raised the possibility that different diabetic agents may
have varying effects on macroangiopathy. The cardiovascular protective effect of metformin,
however, was lost for unexplained reasons when it was used in combination with sulfonylureas.
Since meticulous control of diabetic hyperglycemia has not been consistently effective in
combating macroangiopathy, other etiologies have been studied. Insulin resistance and the
resultant hyperinsulinemia may be key factors.
Insulin is a growth factor, which theoretically, accelerates atherogenesis through
vasculature smooth muscle cell and connective tissue proliferation, as well as increased platelet
adhesiveness (14). Hyperinsulinemia has been predictive for CVD in non-diabetic patients in the
Helsinki Policemen Study (15), the Paris Prospective Study (16), and the Quebec Cardiovascular
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Study (17). Second, insulin resistance and hyperinsulinemia are often found in conjunction with
other cardiovascular risk factors, such as visceral obesity, impaired glucose tolerance or diabetes,
hypertension, aging, impaired fibrinolysis with increased levels of plasminogen activator inhibitor
(PAI-1), and dyslipidemia (18). When present alone, each component poses a risk factor for
CVD. Since many components are often present simultaneously [known as the insulin resistance
syndrome (IRS)], they may synergistically increase the risk for macrovascular complications.
Insulin resistance may, in fact, be an important causal contributor to the development of
its associated features, including the CVD risk factor, diabetic dyslipidemia. Plasma FFA levels
increase as adipocytes become resistant to the anti-lipolytic effects of insulin. Elevated FFA, then
in turn, contribute to the decline in (3 cell function. Additionally, FFA coupled with high levels of
glucose, as seen in T2DM patients, provide the main substrates necessary for TG-rich very low
density lipoprotein (VLDL-C) production by the liver. Lipoprotein lipase (LPL), which
hydrolyzes chylomicrons and VLDL-C to higher density lipoproteins, is also regulated by insulin.
Insulin resistance renders this enzyme less effective. This combined decrease in VLDL-C
clearance in conjunction with elevated VLDL-C production results in the most common lipid
abnormality present in diabetic patients, hypertriglyceridemia (19, 20, 21). Hypertriglyceridemia,
in turn, leads to the formation of smaller, more dense LDL-C cholesterol particles (22). LDL-C
levels are not necessarily elevated in T2DM patients, but small, dense LDL-C particles are more
easily oxidized and therefore, more atherogenic (23, 24). HDL-C levels are decreased in these
patients, again, secondary to decreased production, as well as hypertriglyceridemia (17).
Treating dyslipidemia is extremely beneficial in preventing the development of CVD in
T2DM patients. Elevated total cholesterol, LDL-C, and TG, as well as depressed HDL-C have all
been shown to be independent risk factors for CVD (25, 26). Additionally, studies have
suggested that diabetics may be affected more by abnormalities in the lipid metabolism than non¬
diabetics. The Multiple Risk Factor Intervention Trial, for example, showed that in all patients,
elevated total cholesterol was related to mortality due to coronary heart disease (27). However, in
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patients with a similar degree of hypercholesterolemia, diabetic males had a fourfold greater risk
for heart disease than their non-diabetic controls.

Treatments for T2DM
T2DM medications are primarily used to attain glucose control. Sulfonylureas, which
stimulate the release of insulin at lower glycemic thresholds, comprised the first drug class to
become available. Approximately 66% of patients respond to sulfonylureas, although 20% of the
responders eventually require additional medication for adequate glucose control (28).
Sulfonylureas generally have no effect on lipid profiles. Additionally, because they
increase insulin levels, there is speculation that the sulfonylureas have at best, no effect, and at
worst, may potentiate macrovascular complications. They remain, however, the most widely
used oral anti-diabetic agents.
Within the last decade, other agents have also become available in the US. Biguanides,
which were temporarily available in the 1960s and 1970s, made a resurgence in 1995 when
metformin was introduced into the US market (29). Its entry was quickly followed by other
classes, such as the alpha glucosidase inhibitors, the thiazolidinediones (TZDs), and the non¬
sulfonylurea insulin secretagogues. The most interesting of these medications may be the
biguanides and the TZDs. Both are insulin sparing agents which in addition to controlling
glucose levels, may also have beneficial effects on CVD via their effects on diabetic
dyslipidemia.

Metformin, a Biguanide
The anti-hyperglycemic effects of biguanides have been recognized since the 19th
century. At that time, the active ingredient, guanidine, was extracted from the French lilac,
Galega officinalis, to treat diabetic patients (30). Guanidine was later used to synthesize other
biguanides. The first of these, phenformin, became commercially available in the US in the
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1960s. In the 1970s, however, the drug was removed because it was found to increase the risk of
lactic acidosis (29).
Metformin was used for years in Europe and Canada before it became FDA- approved in
December of 1994 (31). This biguanide has proven to be much safer than phenformin. The
estimated incidence of lactic acidosis is .03 per 1000 patient-years of use (31). A majority of
these cases occurred in the setting of incorrect use, for example, in patients with contraindications
such as renal impairment. Approximately 30% of patients experience various side effects, most
notably dose-related GI symptoms such as abdominal pain, nausea, and diarrhea (31). These
symptoms, however, are tolerable for most, with only 5% of patients requiring discontinuation of
the medication (32).
The glucose and HbAlc lowering with metformin is equivalent to that of the
sulfonylureas. Over 90% of patients initially show clinical improvement on metformin (31).
With continued use, however, 5-10%/yr. become less responsive and eventually require
additional medications (31). Unlike sulfonylureas, metformin does not cause hypoglycemia and
has thus been categorized as an “anti-hyperglycemic.”
Metformin’s mechanism(s) of action have yet to be fully elucidated. A majority of
studies suggest that the drug primarily decreases hepatic glucose output by decreasing
glycogenolysis and/or gluconeogenesis. The drug may also have modest effects on increasing
insulin sensitivity of peripheral tissues (33, 34). Some studies have shown that there are similar
declines in glucose and FFA levels. Lower FFA levels could theoretically improve glucose levels
through the Randle cycle (35,36). Perriello et al. showed that there were similar effects in the
suppression of hepatic glucose production, plasma FFA concentration, and rates of lipid
oxidation, along with the increase in rates of glucose oxidation in patients treated with metformin
(35). Meanwhile, Abbasi et al. demonstrated significant decreases in fasting and postprandial
glucose as well as FFA. In their study, metformin resulted in a mean glucose decrease of 17%
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while FFA decreased by 19% (30). However, not all studies have shown significant reductions in
plasma FFA after metformin treatment (37).
Because metformin reduces glucose levels without elevating insulin levels, there has long
been speculation that the drug may also increase peripheral insulin sensitivity, and therefore,
increase peripheral glucose disposal. Metformin is indeed ineffective in the absence of insulin
(31). Studies have, however, yielded conflicting results as to whether improved peripheral
glucose disposal is directly related to the drug or whether it is a secondary effect of improved
glucose control (i.e. improved glucotoxicity) (37, 38, 39), lowering of FFA levels (i.e. improved
lipotoxicity) (40), and/or changes in body weight and composition (37). Postprandial glucose
lowering may also be facilitated by slow glucose absorption by the GI tract attributable to
metformin (41).
Metformin has rapidly gained popularity in part because of its additional beneficial
effects on various cardiovascular risk factors. Experimental models in animals have shown that
metformin alters aortic lipid metabolism, providing a basis for its possible protective effects
against atherosclerosis (42). In the UKPDS, overweight patients treated with metformin
monotherapy experienced significantly fewer macrovascular events than the control group and
the groups treated with sulfonylurea or insulin (8). This benefit may be secondary to a multitude
of factors. Metformin is an insulin sparing drug, it does not cause weight gain (43, 44), and it has
been shown in some studies to have lipid lowering effects (Table 1). Overall, metformin appears
to significantly lower total cholesterol, LDL-C, and TG, while modestly decreasing FFA and
causing no significant change in HDL-C (62). Additionally, increased fibrinolytic activity and
decreased platelet aggregation, as well as decreased blood pressure and peripheral arterial
resistance have also been demonstrated (53).
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TABLE 1: LITERATURE REVIEW OF THE EFFECTS ON LIPID
METABOLISM OF METFORMIN
Lipid Parameter

Percent Change

Total Cholesterol

No significant change (40) or up to 17%
decrease (49,51,55,58, 59, 60)

VLDL-C

No significant change (40) or up to 39%
decrease (46, 52, 56, 57, 58)
No significant change (51, 61) or up to 24%

LDL-C

decrease (55, 59, 60)
No significant change (35, 61) or up to 17%

HDL-C

increase (45, 46, 51, 55)
No significant change (45, 47, 48) or up to

TG

45% decrease (46, 49, 50, 51, 52, 53, 54, 55)
No significant change (45) or up to 17%

FFA

decrease (35, 46)

Troglitazone, a TZD
TZDs comprise the other class of diabetic medications which may have beneficial CVD
effects. In 1997, troglitazone became the first TZD introduced into the US market (28).
Troglitazone was synthesized with an a-tocopherol moiety, similar in structure to vitamin E, in
hopes of producing a TZD which would not only control hyperglycemia, but could also lower
lipids via limiting lipid oxidation (63). Troglitazone was eventually removed from the US market
by the FDA because of its link to rare idiosyncratic hepatocellular injury. New TZDs, such as
rosiglitazone and pioglitazone, are now available with significantly safer side effect profiles.
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Troglitazone has the same glucose lowering ability as sulfonylureas or metformin in
diabetic patients (64). The drug is not associated with hypoglycemia, and therefore, is also
referred to as an “anti-hyperglycemic”. Its mechanism of action is insulin sensitization, which
primarily occurs in peripheral tissues but may also affect hepatic glucose production (65). To
exert its effect, the drug requires the presence of insulin (66, 67). In a study by Suter et al., 25%
of patients treated with 3 months of troglitazone (400mg QD) had no clinical response (68).
Interestingly, these patients also had the lowest levels of insulin secretion.
TZDs regulate insulin induced gene expression by activating various nuclear receptors of
the peroxisome proliferator activated receptor (PPAR) family (69). PPAR-a, which is found in
tissues such as the liver, kidney, heart, and muscle, is involved in fatty acid metabolism. The
mechanism of action of the lipid lowering fibrates is via this particular receptor. TZDs primarily
work via another member of the superfamily, PPAR-y, which is found in adipose tissue. It
stimulates glucose disposal by increasing transcription of glucose transporters, GLUT1 and
GLUT4, necessary for glucose uptake (69). Since PPARs are also found on vascular wall cells,
theoretically, TZDs could directly affect the vasculature to prevent atherogenesis (70). Glucose
lowering effects have also been associated with increased (3 cell responsiveness. (71).
Like biguanides, TZDs also have multiple beneficial effects on CVD risk factors. They
increase insulin sensitivity resulting in decreased insulin levels, perhaps even to a greater degree
than metformin. The drug also appears to improve dyslipidemia (Table 2). Overall, review of the
literature suggests that troglitazone may significantly decrease TG and FFA, while increasing
total cholesterol, LDL-C, and HDL-C. The effects of troglitazone on the lipid profile appear to
be dose dependent (71).

10

TABLE 2: LITERATURE REVIEW OF EFFECTS ON LIPID METABOLISM OF
TROGLITAZONE
Lipid Parameter

Percent Change

Total Cholesterol

No significant change (71, 73, 77) or up to
5.8% decrease

LDL-C

No significant change (47, 63, 77) or up to
15.4% increase (71, 74, 75, 78)

HDL-C

No significant change (71, 75) or up to 24%
increase (47, 73, 74, 76, 77)

TG

No significant change (71, 74, 75) or up to 32%
decrease (47, 63, 72, 73, 76, 77)

FFA

No significant change (71) or up to 33%
decrease (72, 73)

TZDs have been shown to appreciably affect TG and FFA. A study by Maggs et al.
demonstrated that varying doses of troglitazone had beneficial effects on both fasting and
postprandial TG while higher doses were needed to significantly decrease FFA (79). The effects
of troglitazone on TG lowering are thought to be secondary to decreased hepatic production as
well as increased LPL activity. The role of insulin sensitization in lowering TG levels, however,
is not entirely clear. A study by Saltiel et al. found that insulin deficient mice treated with
troglitazone demonstrated similar decreases in TG as their insulin resistant counterparts (80),
suggesting a direct hypolipidemic effect. The increase in LDL-C found in a majority of studies is
of particular interest (63). Though elevated LDL-C is an independent risk factor for
macrovascular complications, in this case, it may not be as detrimental as expected. Various
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studies have shown that though LDL-C levels are elevated in patients using troglitazone, the ratio
of LDL-C to HDL-C (71) or the ratio of HDL-C to total cholesterol (75) remains unchanged.
Additionally, larger and less dense LDL-C particles have been noted in patients treated with
TZDs (77, 78, 81). These particles may not as prone to oxidation as the smaller dense LDL-C
particles and may therefore, be less atherogenic.
TZDs also lower blood pressure, improve fibrinolysis, decrease platelet aggregability,
and improve endothelial function (63). Further studies are necessary to evaluate whether these
changes are actually associated with positive clinical outcomes.
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STATEMENT OF PURPOSE AND HYPOTHESIS
Macrovascular complications are a significant cause of morbidity and mortality in T2DM
patients. Strict glucose control, which has been shown to prevent and/or forestall the
development of microangiopathy, has had no appreciable effect on the outcome of
macroangiopathy, resulting in a search for other etiologies, as well as preventive strategies.
Insulin resistance and its associated clinical features have become targets of interest.
Metformin and troglitazone are two insulin sparing diabetic agents which function via
different mechanisms, but have comparable glucose lowering effects. Previous studies have also
demonstrated that these two agents benefit diabetic dyslipidemia, a significant risk factor for
CVD. However, their effects on lipid metabolism have not been adequately compared in a single
study.

Therefore, we conducted this study with the following aims in mind:
1.

To characterize the effects of metformin or troglitazone monotherapy on the lipid profiles
[LDL-C, HDL-C, fasting and postprandial FFA, and fasting and postprandial TG] of
T2DM patients.

2.

To characterize the effects of metformin and troglitazone combination therapy on the
lipid profiles [LDL-C, HDL-C, fasting and postprandial FFA, and fasting and
postprandial TG] of T2DM patients.

3.

To determine whether significant lipid altering effects correlate with changes in any of
the following parameters: glucose, HbAlc, basal and clamp glucose production, or
glucose disposal.

We hypothesized that since insulin resistance is believed to be a causal factor of IRS, that
overall, troglitazone will be more effective in controlling dyslipidemia than metformin. Second,
because metformin may also have minor insulin sensitizing properties, we expect that metformin
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and troglitazone combination therapy will be more effective in improving lipids than metformin
or troglitazone monotherapy.
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METHODS
The Human Investigation Committee at Yale University School of Medicine reviewed
and approved the protocol for the original study (64) as well as the use of its data for this project.

Study Subjects
The original study compared the anti-hyperglycemic potential as well as the mechanisms
of action of metformin and troglitazone, when used alone and in combination. All 29 participants
met the National Diabetes Data Group’s criteria for T2DM, with glycosylated hemoglobin values
above the upper limit of normal and plasma C-peptide concentrations > 1.5ng/mL (.50 nmol/L)
on diet, sulfonylurea, and/or biguanide therapy. The following patients were excluded from the
study: pregnant females, patients with abnormal renal or hepatic function, and those with recent
atherosclerotic events.
Initially, patients were randomly distributed between 2 treatment groups: the metformin
and troglitazone monotherapy groups. Both patients and investigators were aware of their
treatment. Of the 15 patients (8 females and 7 males) who were in the metformin monotherapy
group, 1 patient continued on his outpatient antilipid medication and was placed on a submaximal
metformin dose as a consequence of its side effects. Of the 14 patients (8 males and 6 females)
who were initially enrolled in the troglitazone group, data for only 12 patients (5 males and 7
females) was available for this study. One patient continued to have glucose levels >350mg/dL
and was therefore unable to complete 3 months of monotherapy. Meanwhile, a second patient did
not have a substantial portion of their lipid data available. Three patients in the troglitazone
monotherapy group were on anti-lipid medication, which remained stable during the study period.
After the initial 3 months of metformin or troglitazone monotherapy, patients were
invited to continue an additional 3 months of metformin and troglitazone combination therapy.
One patient in the metformin monotherapy group declined further participation. (The patient who
was originally on the anti-lipid medication as well as a submaximal metformin dose continued
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into the combination phase.) In the troglitazone monotherapy group, 1 patient declined the
invitation and 2 additional patients were unable to complete the combination phase because of
unrelated illness. One troglitazone patient on anti-lipid medication continued into the
combination phase.

Study Design
Monotherapy and Combination Therapy
Patients were given a 2 week washout period, during which they discontinued their
outpatient diabetes medication. They were then given either metformin lOOOmg BID or
troglitazone 400mg QD for 3 months. (One patient received a submaximal daily metformin dose
of 1500mg.) At month 0 and month 3, patients were admitted for an 8-hr mixed meal-tolerance
test and a hyperinsulinemic-euglycemic clamp study.
Patients who continued the second phase of the study were placed on metformin and
troglitazone combination therapy for an additional 3 months. At month 6, patients were again
admitted for their last 8-hr mixed meal-tolerance test and a hyperinsulinemic-euglycemic clamp
study.
A diet comprised of 50% carbohydrate, 34% fat, and 16% protein was recommended for
all participants to maintain baseline body weight during the course of the study.
Meal Tolerance Test
The meal tolerance test was performed after an overnight fast. At approximately 8 AM,
for breakfast, and again at 12 PM, for lunch, patients were given Sustacal-HC liquid formula
meals. A fasting blood sample was drawn prior to breakfast followed by eight hourly
postprandial blood samples drawn from an intravenous catheter placed in the antecubital vein.
Blood samples were sent to Coming Nichols Institute where glucose, HbAlc, insulin, C-peptide,
HDL-C, LDL-C, FFA, and TG levels were determined.
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Hyperinsulinemic-Euglycemic Clamp Study and Resulting Measurements
The hyperinsulinemic-euglycemic clamp study using [6,6-:H] glucose was performed the
following day after an overnight fast (64). Gas chromatography-mass spectrometry was done at
the Yale Stable Isotope Core Facility. The substrate and hormone measurements were
determined as follows:
1. Basal Endogenous Glucose Production = (f/BSA)x([enrichmentinf/enrichmentpiasma] - 1)
f= basal [6,6-'H] glucose infusate rate (mg/min)
BSA = body-surface area (in)
enrichment^ = % enrichment of [6,6- H] glucose enrichment
enrichment^^ = % of plasma [6,6-' H] glucose enrichment

2. Glucose Disposal Rate = cEGP + GIR
cEGP = endogenous glucose production during clamping (see below for calculation)
GIR = Mean rate of exogenous glucose infusion from minutes 260 to 300 of the clamping period
2
(mg/m /min)

3. Endogenous Glucose Production During Clamping = GIR x ([enrichmentjnr/enrichmentpiasma] -

i)

Data Collection and Statistical Analysis
For this project, charts collected from the original study were reviewed. Patients’ lipid
and glucose profiles were entered into a Microsoft Excel database. Postprandial values were
calculated as the mean of the 8 existing hourly measurements.
To determine the effects of metformin and troglitazone, alone and in combination, on the
lipid metabolism of patients with T2DM, statistical analysis was performed on the following 3
distinct data sets:
1.

Patients who completed the initial 3 months were analyzed separately depending on the
treatment group they were initially placed to directly compare the effects on the lipid
metabolism of metformin and troglitazone when used alone.
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2.

Patients who completed six months were analyzed together regardless of their initial
monotherapy group to analyze the effects on the lipid metabolism of metformin and
troglitazone when used in combination.

3.

Patients who completed six months were analyzed separately depending on their initial
monotherapy treatment to compare the effects of adding troglitazone to metformin
monotherapy versus adding metformin to troglitazone monotherapy.

Lipid parameters which were significantly affected underwent a second phase of analysis.
Regression analysis was performed to determine whether changes in lipid levels correlated
significantly with changes in glucose, HbAlc, basal endogenous glucose production, endogenous
glucose production during the clamp study, and/or glucose disposal rates.
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RESULTS
Patient Characteristics
The metformin and troglitazone groups had similar baseline characteristics. Fifteen
patients, 8 women and 7 men, were included in the analysis of the metformin monotherapy group.
This group was comprised of 12 Caucasians, 2 African Americans, and 1 patient of mixed
African American and Native American ancestry. Ages ranged from 32 to 74 years with a mean
age of 51±13 years, while the duration of diabetes ranged from 3 months to 14 years with a mean
duration of 5±4 years. Prior to the start of the study, 8 patients were taking sulfonylureas, 1 was
taking metformin, 4 were taking sulfonylurea and metformin combination therapy, and 2 were
diet controlled. The mean body mass index (BMI) was 33.9±6.8 kg/m2. Twelve patients, 7
women and 5 men, were included in the analysis of the troglitazone monotherapy group. This
group was comprised of 10 Caucasians, 1 African American, and 1 patient of mixed African
American, Native American, and Dutch ancestry. Ages ranged from 37 to 71 years old with a
mean age of 56+12 years, while the duration of diabetes ranged from 2 months to 12 years with a
mean duration of 3±3 years. Prior to the start of the study, 8 patients were taking sulfonylureas, 1
was taking metformin, and 3 were diet controlled. The mean BMI was 32.7±7.4 kg/m2 (Table 3).
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TABLE 3: BASELINE DEMOGRAPHICS OF PATIENTS WHO COMPLETED THE
INITIAL 3 MONTHS OF MONOTHERAPY
Patient Characteristics

Metformin Monotherapy

Troglitazone Monotherapy

(N=15)

(N=12)

Age (yr)

51± 13

56112

Race

2 African Americans (13%)

1 African American (8%)

1 African American and

1 African American. Native

Native American (7%)

American, and Dutch (8%)

12 Caucasians (80%)

10 Caucasians (83%)

8 Females (53%)

7 Females (58%)

7 Males (47%)

5 Males (42%)

Anti-diabetic Medication(s)

8 on Sulfonylureas

8 on Sulfonylureas

Prior to Study

1 on Metformin

1 on Metformin

4 on Combination Therapy1

3 Diet Controlled

Gender

2 Diet Controlled
Duration of Diabetes (yr)

5 ±4

313

Body Mass Index (kg/m2)

33.916.8

32.717.4

*p>0.05 for above patient characteristics
1Patients on combination therapy were on sulfonylureas and metformin
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The patients in the metformin and troglitazone groups also had similar fasting lipid and
diabetes profiles obtained at month 0 (after the washout period and prior to the start of
monotherapy) (Table 4).

TABLE 4: FASTING VALUES OBTAINED AT MONTH 0 AFTER THE WASHOUT
PERIOD
Fasting Parameter

Metformin Group

Troglitazone Group

(N=15)

(N=12)

Glucose (mg/dL)

287+84

273170

Glycosylated hemoglobin (%)

10.011.6

9.611.7

HDL-C (mg/dL)

40.7110.1

40.6+8.0

LDL-C (mg/dL)

122.4133.2

133.9135.0

TG (mg/dL)

191.31118.1

228.9+161.2

FFA (nmol/L)

.871.27

.981.42

*p>0.05 far above fasting parameters

Monotherapy (Table 5)
After the initial 3 months, metformin and troglitazone monotherapy had similar
insignificant effects on HDL-C. Metformin increased HDL-C from 40.7±10.1 to 43.2± 15.1
mg/dL (+6.0%; P=.27) while troglitazone increased levels from 40.6±8.0 to 43.1±8.7 mg/dL
(+6.2%; P=. 14) (Figure 1). In contrast, there was a significant difference between their effects on
LDL-C. Troglitazone increased LDL-C from 133.9+35.0 to 144.8+37.3 mg/dL (+8.1%; P=.ll),
while metformin decreased levels from 122.4133.2 to 113.2132.5 mg/dL (-7.5%; P=.036) (Figure
2). LDL-C lowering effects seen with metformin did not correlate with changes in glucose.
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HbAlc, basal endogenous glucose production, endogenous glucose production during the clamp
study, or glucose disposal rates.
Metformin and troglitazone monotherapy did not appreciably alter fasting (Figure 3) or
postprandial TG levels (Figure 4). Metformin decreased fasting TG by 15.3% (P=.097), from
191.3± 118.1 to 162.0± 77.9 mg/dL, and postprandial TG by 9.8% (P=.15), from 253.2±116.6 to
228.4±95.5 mg/dL. Similarly, troglitazone decreased fasting TG by 16.4% (P=.43), from
229.0±161.2 to 191.31101.9, and postprandial TG by 9.7% (P=. 18), from 290.71147.9 to
262.61128.0.
Metformin did not affect fasting FFA (Figure 5). Levels decreased .27% (P=.96), from
.8731.271 to .8711.227 nmol/L. Troglitazone significantly decreased fasting FFA by 30.0%
(P=.033) from .981.42 to .691.24. This decrease correlated with changes in fasting glucose
(R=.68; p=.016) (Figure 6). Both medications decreased postprandial FFA levels (Figure 7).
Metformin decreased postprandial FFA levels from .391.20 to .261.13 nmol/L (-32.7%;
P=.0091) and troglitazone decreased levels slightly more, from .371.21 to .191.10
(-48.7%; P=.0013). Postprandial FFA lowering did not correlate with any changes in the glucose
parameters.

TABLE 5: EFFECTS OF METFORMIN OR TROGLITAZONE MONOTHERAPY ON LIPID PROFILES
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Combination Therapy (Table 6)
Three months of metformin and troglitazone combination therapy significantly
increased HDL-C by 12% (P=.0044), from 40.4±9.1 to 45.3+12.8 mg/dL (Figure 1). There was
no correlation between the HDL-C increase and changes in glucose parameters. When patients
who completed the entire 6 month study were analyzed according to their initial monotherapy
group, adding troglitazone to metformin appreciably increased HDL-C by 7.7% (P=.012).
Regarding LDL-C, the addition of metformin to troglitazone significantly decreased levels by
12.4% (P=.009). However, there was no significant overall LDL-C difference with combination
therapy (-1.6%; P=.66) (Figure 2).
Combination therapy decreased fasting and postprandial TG by 27.0% (P=.0083), from
219.7+145.3 to 160.5+117.6 mg/dL (Figure 3) and 15.1% (P=.0059), from 265.2+117.1 to
225.2+122.6 mg/dL respectively (Figure 4). Fasting and postprandial FFA also appreciably
decreased. Fasting FFA decreased from .94+.35 to .78+.21 nmol/L (-17.3%; P=.0017) (Figure 5)
while postprandial FFA decreased from .38+.21 to .18+. 12 (-53.0%; P=2.5E-Q7) (Figure 7).
Adding troglitazone significantly decreased fasting FFA by 15.4% (P=.Q35) and postprandial
FFA by 38.14% (P=.0029). These significant changes did not correlate with any changes in the
glucose parameters.

TABLE 6: EFFECTS OF COMBINATION THERAPY ON LIPID PROFILES (N=23)
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DISCUSSION
Our study demonstrates that metformin and troglitazone had similar insignificant effects
on HDL-C. The marginal effect on HDL-C seen with metformin is consistent with the literature.
However, past studies have demonstrated that troglitazone can appreciably increase HDL-C
levels in patients with T2DM (45, 46, 51, 55). The reason for the discrepancy between our
findings and the existing literature is unclear. A plausible explanation may be an insufficient
sample size of the troglitazone monotherapy group. In fact, not only did HDL-C concentrations
rise significantly with combination therapy, but also, the addition of troglitazone to the metformin
monotherapy group appreciably increased HDL-C levels. This suggests that the greater sample
size found in the combination group may have allowed the effect of troglitazone on HDL-C
elevation to become statistically evident. The significant effect seen with combination therapy
also raises the possibility that simultaneous metformin and troglitazone administration may have
some additive beneficial effects on CVD risk.
The divergent effects of metformin (55, 59, 60) and troglitazone (71, 74, 75, 78) on LDLC are consistent with past studies. Metformin demonstrated significant LDL-C lowering effect.
Its effects were significantly better than troglitazone, which marginally elevated LDL-C instead.
Additionally, metformin and troglitazone administered simultaneously overall had a neutral effect
on LDL-C. Although LDL-C lowering seen with metformin are noteworthy and may play a
beneficial role in cardiovascular risk reduction as was implied by the UKPDS (8), the
implications of LDL-C elevation with troglitazone are less clear. The LDL-C increase may be
secondary to LDL-C particle size. As was previously mentioned, patients treated with
troglitazone are noted to have larger, more buoyant LDL-C particles, which may be less
susceptible to oxidation, and therefore, less atherogenic (77, 78, 81). Because calculated LDL-C
is affected by both the number and size of the particles, it is difficult to ascertain in this study,
which component was actually responsible for the elevation in the troglitazone treated group.
Future studies which measure apoprotein B levels in conjunction with LDL-C levels or directly
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measure LDL particle size (through ultracentrifugation techniques) will be helpful for
clarification.
Metformin and troglitazone had minimal effects on fasting and postprandial TG when
used alone, but significantly decreased these parameters when used in combination. The
monotherapy results contradicted existing literature. Most studies demonstrate that both antihyperglycemics lower overall TG levels, with troglitazone faring somewhat better (46, 47, 49, 50,
51, 52, 53, 54, 55, 63, 72, 73, 76, 77). TG reduction seen with metformin treatment is attributed
to decreased hepatic VLDL-C synthesis. Troglitazone, however, is believed to decrease the
precursors for TG production through insulin sensitization and/or direct anti-lipolytic effects on
adipocytes. The discrepancy between our monotherapy results and the existing literature may
again, be attributable to the sample size. The ability of combination therapy to significantly
reduce fasting and to a lesser magnitude, postprandial TG, is possibly secondary to the larger
sample size or may again be due to an additive effect achieved with combination therapy.
Last, this study demonstrated the effects of metformin and troglitazone on fasting and
postprandial FFA. Troglitazone had significant effects on fasting FFA. Not only did it decrease
FFA to a significantly greater extent than metformin, but also, the addition of troglitazone to
metformin monotherapy significantly lowered fasting FFA in this subgroup of patients.
Combination therapy seemed to offset the degree of reduction seen with troglitazone alone.
Meanwhile, both metformin and troglitazone significantly decreased postprandial FFA when used
alone and in combination, postprandial FFA were decreased to a slightly greater extent. These
results are similar to existing studies. Metformin has yielded inconsistent FFA results (35, 45,
46) whereas troglitazone has been noted to consistently decrease overall FFA (72, 73).
Troglitazone works through the nuclear receptor, PPAR, which is predominantly found in adipose
tissue (69, 70). Therefore, its insulin sensitizing properties may work directly through fat cells by
decreasing lipolysis, and, therefore, FFA release. Indeed, there was a greater FFA percentage
change found in the postprandial state, when insulin is more abundant, than in the fasting state.
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The decrease of fasting FFA in the troglitazone group was the sole parameter found to
correlate with glucose lowering. The reason is unclear. Perhaps a decrease in glucotoxicity
facilitated improved FFA metabolism or vice versa. Theoretically, a relationship does exist
between FFA and glucose through the Randle cycle. There is speculation that medications which
decrease FFA improve insulin sensitivity, which then facilitates glucose disposal and oxidation in
muscle and fat, and decreases hepatic glucose production in liver. There was, however, no
significant correlations found between fasting FFA and glucose production and/or glucose
disposal.
This study, which directly compared the effects on lipid metabolism of metformin and
troglitazone, when used alone and in combination, had limitations. Data was derived from an
original prospective study that was not designed to analyze changes in lipid metabolism, but
rather, changes in glucose and FlbAlc. Therefore, the small sample size may not be powered to
identify all of the significant changes in the lipid parameters. In addition, the lipid profiles of
patients may have been affected by factors other than the oral anti-hyperglycemic medications.
Several patients were on anti-lipid medications. However, since these patients had been taking
anti-lipid medications prior to the study and then continued on a fixed constant dosage throughout
the study, it was not expected to be a significant confounder. Second, a diet comprised of 50%
carbohydrate, 34% fat, and 16% protein was recommended to all participants to maintain baseline
body weight. Although diet does beneficially affect lipid metabolism, all participants were
encouraged to follow the same diet. In addition, all values were obtained at least 2 weeks after
diet recommendations were made. This 2 week washout period should have provided sufficient
time for changes attributable to diet alone to become evident.
Although a small pool of patients was analyzed, there were several significant findings.
This study demonstrated that metformin and troglitazone may have comparable antihyperglycemic effects (64), but have differing effects on lipid metabolism. Metformin, which
primarily decreases hepatic glucose production, was found to significantly alter LDL-C and
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postprandial FFA, whereas troglitazone, an insulin sensitizer with effects primarily on adipose
tissue, appreciably decreased fasting and postprandial FFA. When used in combination,
metformin and troglitazone demonstrated additive effects, most notably on HDL-C and fasting
and postprandial TG, and to a much lesser degree, on postprandial FFA.
The beneficial effects on diabetic dyslipidemia demonstrated by metformin and
troglitazone, both alone and in combination, are intriguing. These effects may indeed play a
crucial role in reducing the risk for CVD, which is the major cause of mortality in T2DM
patients. Additionally, the beneficial effects of troglitazone and possibly other TZDs on FFA (ie.
improved lipotoxicity) may not only reduce macrovascular complications, but also improve (3 cell
function. Further larger scale prospective studies are needed to better understand the long-term
clinical implications of these effects.
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